Claims
- 1. A compound of the formula:
- 2. The compound according to claim 1, wherein the compound is selected from any one of the compounds depicted in Table 1.
- 3. A pharmaceutical composition comprising an amount of a compound according to either of claims 1 or 2 effective to inhibit JNK, and a pharmaceutically acceptable carrier.
- 4. A method of treating or preventing inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, neurodegenerative diseases, allergies, reperfusion/ischemia in stroke, heart attacks, angiogenic disorders, organ hypoxia, vascular hyperplasia, cardiac hypertrophy, thrombin-induced platelet aggregation or conditions associated with proinflammatory cytokines in a patient, said method comprising administering to said patient a composition according to claim 3.
- 5. The method according to claim 4, wherein said method is used to treat or prevent an inflammatory disease selected from acute pancreatitis, chronic pancreatitis, asthma, allergies, or adult respiratory distress syndrome.
- 6. The method according to claim 4, wherein said method is used to treat or prevent an autoimmune disease selected from glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Graves' disease, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, atopic dermatitis, chronic active hepatitis, myasthenia gravis, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, psoriasis, or graft vs. host disease.
- 7. The method according to claim 4, wherein said method is used to treat or prevent a destructive bone disorders selected from osteoarthritis, osteoporosis or multiple myeloma-related bone disorder.
- 8. The method according to claim 4, wherein said method is used to treat or prevent a proliferative disease selected from acute myelogenous leukemia, chronic myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, or multiple myeloma.
- 9. The method according to claim 4, wherein said method is used to treat or prevent neurodegenerative disease selected from Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, cerebral ischemia or neurodegenerative disease caused by traumatic injury, glutamate neurotoxicity or hypoxia.
- 10. The method according to claim 4, wherein said method is used to treat or prevent ischemia/reperfusion in stroke or myocardial ischemia, renal ischemia, heart attacks, organ hypoxia or thrombin-induced platelet aggregation.
- 11. The method according to claim 4, wherein said method is used to treat or prevent a condition associated with T-cell activation or pathologic immune responses.
- 12. The method according to claim 4, wherein said method is used to treat or prevent an angiogenic disorder selected from solid tumors, ocular neovasculization, or infantile haemangiomas.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of co-pending International Application PCT/US00/15248, filed Jun. 2, 2000, which claims priority of U.S. provisional patent application No. 60/237,523, filed Jun. 3, 1999.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60137523 |
Jun 1999 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/US00/15248 |
Jun 2000 |
US |
Child |
10008277 |
Dec 2001 |
US |